GlassScriptPhysician profile
Po Long Lew
NPI 1235145350
$23,792.12
in general payments reported to CMS, 2019-2025
60 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,756 · 2020: $3,484 · 2021: $5,134 · 2022: $4,118 · 2023: $1,992 · 2024: $2,048 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,299.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,789.76 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Mannkind Corporation | $2,322.35 | 2019-2025 | Afrezza |
| Horizon Therapeutics Plc | $1,864.26 | 2019-2023 | Krystexxa |
| Abbvie INC. | $1,161.88 | 2019-2024 | |
| Pfizer INC. | $1,093.43 | 2019-2024 | |
| Esperion Therapeutics, INC. | $1,004.59 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $990.37 | 2019-2024 | Breztri, Airsupra |
| Sunovion Pharmaceuticals INC. | $852.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $835.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $829.65 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $654.76 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $590.43 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.40 | 2019-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $520.83 | 2023-2025 | Voquezna |
| Amarin Pharma, INC. | $510.02 | 2019-2023 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Po Lew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.